ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

enzalutamide

Also written as “Enzalutamide”, “MDV3100” and “HC-1119”.

Its studies are mostly in Prostatic Neoplasms · Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis, led by 6 companies.

Drug pageEnzalutamide: every studyMany companies study it; this page follows only the 54 they lead. All 176 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 31, 201354 company-led studies, 7 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharmaits history only313 open or runningphase 4since Oct 31, 2013Jan 18, 2011Apr 30, 2027phase 1 · NCT07783282
Pfizerits history only162 open or runningphase 4since Nov 18, 2013Jul 31, 2007none ahead
Hinova Pharmaceuticals41 open or runningphase 3since Feb 17, 2019Dec 11, 2018none ahead
Alessa Therapeuticsits history only11 open or runningphase 1since Dec 14, 2023Dec 14, 2023Dec 30, 2028phase 1 · NCT06257693
Applied Biologyits history only10 open or runningphase 3since Jul 28, 2021Jul 28, 2021none ahead
Hinova Pharmaceuticals USAits history only10 open or runningphase 3since Feb 20, 2019Feb 20, 2019none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Medivation LLC, a wholly owned subsidiary of Pfizer and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hinova Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2018First studies: 3 phase 1 studies in Metastatic Castration Resistant Prostate CancerFirst studyNCT03778047, NCT03776968, NCT03774056
  2. Feb 17, 2019Phase 3 study in MCRPCNCT03851640 · 417 planned · China

TargetBeta

AR →read by rule
“A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 4 Hinova Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03851640MCRPC · China3RecruitingSep 2025417
NCT03778047Metastatic Castration Resistant Prostate Cancer · China1CompletedOct 24, 201810
NCT03776968Metastatic Castration Resistant Prostate Cancer · China1CompletedJan 15, 201847
NCT03774056Metastatic Castration Resistant Prostate Cancer · China1CompletedSep 26, 201843

How it is read

Names in the registry

  • “Enzalutamide”, 40 entries
  • “enzalutamide”, 13 entries
  • “MDV3100”, 8 entries
  • “HC-1119”, 4 entries
  • “HC1119”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.